Abramson Cancer Center hematologic malignancies’ clinicians and researchers have led the way nationally for years; both in the care of patients with hematologic malignancies (blood cancer) and in its research.
Today, there's more hope than ever for those who face a blood cancer diagnosis.
Penn’s program is one of the oldest and largest in the country. By putting our experience to work, we offer the best possible treatment outcomes.
Penn has one of the few Hematologic Malignancy (leukemia, lymphoma and myeloma) Research Programs in the country that is approved and funded by the National Cancer Institute. It is through this research program that Penn has made significant advances in improving bone marrow and stem cell transplants and the care of patients with blood cancer.
The knowledge gained through our research allows us to better care for those with blood cancers.
To learn about what sets us apart, visit:
In 2003 her doctors found a cancerous brain tumor, estimating that she had a year and a half to live. Sallie Nangeroni wanted the best neurosurgeon in the region. She came to HUP. Sally was rightfully scared. Her father died of brain cancer when he was just 40 years old, and her husband's brother had just passed away from a brain tumor. At the time she was diagnosed, Sallie just hoped that she would be able to see all three of her sons graduate from high school. Now, 7 years later, she has seen two of them graduate from college, with one now in medical school. Her next goal is to see her youngest son graduate from college next year.
Focus On Blood Cancers and Bone Marrow Transplant Video
A patient education video with testimonies from our patients, doctors and researchers. Find out more about programs, treatment, research and care that is unique to the Abramson Cancer Center.